Trial Profile

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Nov 2025 Results presented in the Attralus Media Release
04 Nov 2025 According to Attralus media release, data from the trial will be presented at the upcoming 67th ASH Annual Meeting and Exposition in Orlando, FL on December 6-9, 2025.
08 Sep 2025 According to Attralus media release, data from this study will be presented at , at the American Society of Nuclear Cardiology Annual Scientific Session & Exhibition (ASNC) held in Orlando, FL on September 4-7, 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com